{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:32:43Z","timestamp":1760783563300},"reference-count":0,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[1992,8,1]],"date-time":"1992-08-01T00:00:00Z","timestamp":712627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1992,8]]},"abstract":"<jats:p>RU44790 belongs to a new class of synthetic monocyclic beta-lactam antibiotics which feature a bioisosteric tetrazole moiety instead of the more classical acidic functions at the N-1 position of the beta-lactam ring. Its antibacterial activity was evaluated against some 900 strains and was compared with those of other recent beta-lactam derivatives, especially aztreonam. RU44790 is endowed with potent activity against gram-negative bacteria. At less than or equal to 0.6 micrograms\/ml, RU44790 inhibited 90% of all strains of the family Enterobacteriaceae with the exception of Citrobacter spp. (MIC for 90% of strains tested, 1.2 micrograms\/ml). The activity was similar to that of aztreonam against strains that are normally susceptible to expanded-spectrum cephalosporins. On the other hand, the new compound was 10 to 100 times more potent than aztreonam and most of the other antibiotics tested against enterobacteria that produce chromosome-encoded or plasmid-mediated extended-spectrum beta-lactamases. Pseudomonas aeruginosa isolates were equally susceptible to both monobactams. RU44790 was inactive against staphylococci and had only marginal activity against streptococci (MIC for 50% of strains tested, 2.5 micrograms\/ml). RU44790 was highly resistant to hydrolysis by various beta-lactamases, particularly cephalosporinases such as P99. The latter enzyme was also inhibited by the compound. RU44790 showed a high affinity for penicillin-binding protein 3 of Escherichia coli. The results suggest that RU44790 has good potential in the treatment of infections caused by gram-negative microorganisms.<\/jats:p>","DOI":"10.1128\/aac.36.8.1756","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"1756-1763","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Antibacterial activity of RU44790, a new N-tetrazolyl monocyclic beta-lactam"],"prefix":"10.1128","volume":"36","author":[{"given":"J F","family":"Chantot","sequence":"first","affiliation":[{"name":"Centre de Recherches, Roussel-Uclaf, Romainville, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Klich","sequence":"additional","affiliation":[{"name":"Centre de Recherches, Roussel-Uclaf, Romainville, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Teutsch","sequence":"additional","affiliation":[{"name":"Centre de Recherches, Roussel-Uclaf, Romainville, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bryskier","sequence":"additional","affiliation":[{"name":"Centre de Recherches, Roussel-Uclaf, Romainville, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Collette","sequence":"additional","affiliation":[{"name":"Centre de Recherches, Roussel-Uclaf, Romainville, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Markus","sequence":"additional","affiliation":[{"name":"Centre de Recherches, Roussel-Uclaf, Romainville, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Seibert","sequence":"additional","affiliation":[{"name":"Centre de Recherches, Roussel-Uclaf, Romainville, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.36.8.1756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.36.8.1756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:29:01Z","timestamp":1645457341000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.36.8.1756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,8]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1992,8]]}},"alternative-id":["10.1128\/AAC.36.8.1756"],"URL":"https:\/\/doi.org\/10.1128\/aac.36.8.1756","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,8]]},"assertion":[{"value":"1992-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}